KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Accounts Payables (2018 - 2025)

Twist Bioscience (TWST) has disclosed Accounts Payables for 8 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 66.51% to $12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Dec 2025, up 66.51% year-over-year, with the annual reading at $11.1 million for FY2025, 580.61% up from the prior year.
  • Accounts Payables for Q4 2025 was $12.5 million at Twist Bioscience, up from $11.1 million in the prior quarter.
  • The five-year high for Accounts Payables was $23.1 million in Q4 2021, with the low at $1.6 million in Q3 2024.
  • Average Accounts Payables over 5 years is $12.5 million, with a median of $12.0 million recorded in 2025.
  • The sharpest move saw Accounts Payables plummeted 53.98% in 2023, then soared 580.61% in 2025.
  • Over 5 years, Accounts Payables stood at $23.1 million in 2021, then dropped by 12.83% to $20.1 million in 2022, then tumbled by 53.98% to $9.3 million in 2023, then decreased by 18.94% to $7.5 million in 2024, then soared by 66.51% to $12.5 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $12.5 million, $11.1 million, and $12.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.